X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Piramal Healthcare with ACTAVIS INC. - US - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PIRAMAL ENTERPRISES vs ACTAVIS (US) - Comparison Results

PIRAMAL ENTERPRISES    Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 PIRAMAL ENTERPRISES   ACTAVIS
EQUITY SHARE DATA
    PIRAMAL ENTERPRISES
Mar-17
ACTAVIS
Dec-14
PIRAMAL ENTERPRISES/
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs2,09517,672-   
Low Rs1,02510,779-   
Sales per share (Unadj.) Rs492.83,182.2-  
Earnings per share (Unadj.) Rs72.6-397.1-  
Cash flow per share (Unadj.) Rs94.7292.0-  
Dividends per share (Unadj.) Rs21.000-  
Dividend yield (eoy) %1.30-  
Book value per share (Unadj.) Rs862.56,902.2-  
Shares outstanding (eoy) m172.56265.90-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.24.5 70.8%   
Avg P/E ratio x21.5-35.8 -60.0%  
P/CF ratio (eoy) x16.548.7 33.8%  
Price / Book Value ratio x1.82.1 87.8%  
Dividend payout %28.90-   
Avg Mkt Cap Rs m269,1943,782,610 7.1%   
No. of employees `0004.021.6 18.6%   
Total wages/salary Rs m17,9390-   
Avg. sales/employee Rs Th21,190.339,173.9 54.1%   
Avg. wages/employee Rs Th4,470.10-   
Avg. net profit/employee Rs Th3,120.0-4,888.5 -63.8%   
INCOME DATA
Net Sales Rs m85,037846,156 10.0%  
Other income Rs m2,338-2,112 -110.7%   
Total revenues Rs m87,374844,045 10.4%   
Gross profit Rs m34,991108,701 32.2%  
Depreciation Rs m3,817183,224 2.1%   
Interest Rs m20,31026,689 76.1%   
Profit before tax Rs m13,202-103,324 -12.8%   
Minority Interest Rs m1,6990-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-100-7,579 1.3%   
Tax Rs m2,281-5,312 -42.9%   
Profit after tax Rs m12,520-105,591 -11.9%  
Gross profit margin %41.112.8 320.3%  
Effective tax rate %17.35.1 336.1%   
Net profit margin %14.7-12.5 -118.0%  
BALANCE SHEET DATA
Current assets Rs m87,590445,816 19.6%   
Current liabilities Rs m185,578325,131 57.1%   
Net working cap to sales %-115.214.3 -807.9%  
Current ratio x0.51.4 34.4%  
Inventory Days Days3158 53.5%  
Debtors Days Days4866 71.7%  
Net fixed assets Rs m108,523103,324 105.0%   
Share capital Rs m3450-   
"Free" reserves Rs m148,4810-   
Net worth Rs m148,8261,835,282 8.1%   
Long term debt Rs m144,957961,724 15.1%   
Total assets Rs m482,3943,363,468 14.3%  
Interest coverage x1.7-2.9 -57.5%   
Debt to equity ratio x1.00.5 185.9%  
Sales to assets ratio x0.20.3 70.1%   
Return on assets %6.8-2.3 -290.1%  
Return on equity %8.4-5.8 -146.2%  
Return on capital %12.0-3.0 -396.9%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m9,8510-   
CASH FLOW
From Operations Rs m-100,393145,302 -69.1%  
From Investments Rs m-24,202-347,907 7.0%  
From Financial Activity Rs m135,705195,474 69.4%  
Net Cashflow Rs m11,110-7,132 -155.8%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 64.78 Rs / USD

Compare PIRAMAL ENTERPRISES With: MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare PIRAMAL ENTERPRISES With: NOVARTIS  GSK PHARMA  FRESENIUS KABI ONCO.  JUBILANT LIFE SCIENCES  PLETHICO PHARMA  



Today's Market

Sensex Finishes Firm; Software & FMCG Stocks Gain(Closing)

Indian share markets finished the trading session well above the dotted line, snapping a three-day falling streak amid firm Asian markets.

Related Views On News

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PIRAMAL ENTERPRISES SHARE PRICE


Feb 21, 2018 03:35 PM

TRACK PIRAMAL ENTERPRISES

  • Track your investment in PIRAMAL ENTERPRISES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PIRAMAL ENTERPRISES

PIRAMAL ENTERPRISES 5-YR ANALYSIS

COMPARE PIRAMAL ENTERPRISES WITH

MARKET STATS